| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
St. Joseph's Hospital and Medical Center, Paterson, New Jersey
Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Correspondence: For correspondence or reprints contact: David M. Goldenberg, ScD, MD, Garden State Cancer Center, 520 Belleville Ave., Belleville, NJ 07109-0023.
ABSTRACT
Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities. A complete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (MAb), given intravenously, is reported in a patient with advanced ovarian cancer refractory to paclitaxel (Taxol) therapy. The patient first received radioimmunotherapy with 
74 mCi 131I-MN-14 IgG, followed 4 mo later by a similar dose of radiolabeled MAb. A partial remission was seen by CT 1 mo after the first radioimmunotherapy, and a further objective response was documented after the second radioimmunotherapy. CT scans performed 6 and 11 mo after the second radioimmunotherapy showed stable and minimal residual changes. However, a whole-body PET scan with [18F]fluorodeoxyglucose (FDG-PET) was negative in these regions. The CA-125 also decreased to only 13 U/ml, compared to the baseline value of 7700 U/ml. Based on CT, FDG-PET, serum CA-125 and physical exam, the patient was in complete clinical remission for 8 mo when the CA-125 levels rose. CT also showed a new suspicious lesion, presumably a peritoneal implant. No toxicity was seen after the first injection, and only Grade 1 thrombocytopenia] and Grade 2 leukopenia developed after the second injection, both reversing within 6 wk. This is a report of a complete clinical remission with radiolabeled anti-CEA antibodies in a patient with chemotherapy-refractive metastatic ovarian cancer.
Key Words: ovarian cancer • iodine-131-labeled anti-CEA monoclonal antibody • radioimmunotherapy
This article has been cited by other articles:
|
|
 |
|
  Z. Wang, L. Martensson, R. Nilsson, P.-O. Bendahl, L. Lindgren, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid and Biotin before Radiolabeling Clin. Cancer Res., October 1, 2005; 11(19): 7171s - 7177s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. ter Linden, G. A. van Dongen, and C. F. Molthoff Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN J. Nucl. Med., March 1, 2001; 42(3): 509 - 519. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. Gestin, A. Loussouarn, M. Bardies, E. Gautherot, A. Gruaz-Guyon, C. Sai-Maurel, J. Barbet, C. Curtet, J. F. Chatal, and A. Faivre-Chauvet Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies J. Nucl. Med., January 1, 2001; 42(1): 146 - 153. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
